Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:12:16 EDT Fri 25 Sep 2026
Enter Symbol
or Name
USA
CA



Q:LXRX - LEXICON PHARMACEUTICALS INC - https://www.lexpharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
LXRX - Q0.51.77·2.060.11.795-0.065-3.53,050.45,1815,6711.87  1.93  1.7652.68  1.1019:44:11Sep 0115 min RT 2¢

Recent Trades - Last 10 of 5671
Time ETExPriceChangeVolume
19:44:11Q1.8199-0.0401100
19:44:11Q1.82-0.04100
19:30:06Q1.815-0.0451
19:30:06Q1.81-0.051
19:30:04Q1.815-0.0451
19:30:04Q1.81-0.051
18:39:55Q1.81-0.0521,000
18:20:55Q1.8101-0.04995,000
17:49:52Q1.80-0.061
17:44:10Q1.80-0.0630

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-09-01 16:05U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
2026-08-31 08:30U:LXRXNews ReleaseLexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
2026-08-24 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
2026-08-06 07:30U:LXRXNews ReleaseLexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
2026-07-30 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-27 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
2026-06-03 08:00U:LXRXNews ReleaseLexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
2026-05-28 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-12 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
2026-05-07 07:30U:LXRXNews ReleaseLexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
2026-05-04 16:05U:LXRXNews ReleaseLexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
2026-04-30 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
2026-04-17 08:00U:LXRXNews ReleaseLexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
2026-03-24 08:00U:LXRXNews ReleaseLexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
2026-03-23 07:30U:LXRXNews ReleaseLexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
2026-03-11 08:00U:LXRXNews ReleaseLexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
2026-03-05 06:59U:LXRXNews ReleaseLexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
2026-03-03 16:01U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
2026-02-26 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
2026-02-06 17:17U:LXRXNews ReleaseLexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement